Literature DB >> 21062248

Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity.

T Masaki1, H Yoshimatsu.   

Abstract

Obesity is the effect of imbalance between energy intake and expenditure and forms a fundamental basis of the metabolic syndrome. A number of substances implicated in the regulation of energy metabolism represent opportunities for anti-obesity drug development. Neuronal histamine and its receptors have been shown to regulate energy metabolism and are considered as anti-obesity targets. Several histamine receptor subtypes have been identified; of these, histamine H1 and H3 receptors (H1-R and H3-R) have been specifically recognized as mediators of energy intake and expenditure. In addition, several histamine drugs related to H1-R and H3-R, have been shown to attenuate body weight gain both in rodent and human. These results provide the reagents for histamine receptors biology and may find applications in the treatment of obesity and related metabolic disorders. In this review, the development of agonists and antagonists of histamine receptors are provided.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062248     DOI: 10.2174/092986710794182944

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  3 in total

Review 1.  Histamine receptor signaling in energy homeostasis.

Authors:  Iustin V Tabarean
Journal:  Neuropharmacology       Date:  2015-06-21       Impact factor: 5.250

2.  Systematic analysis of histamine and N-methylhistamine concentrations in organs from two common laboratory mouse strains: C57Bl/6 and Balb/c.

Authors:  Anna Sophie Zimmermann; Heike Burhenne; Volkhard Kaever; Roland Seifert; Detlef Neumann
Journal:  Inflamm Res       Date:  2011-09-13       Impact factor: 4.575

3.  Design, synthesis, and in vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H3 receptor antagonists.

Authors:  Marek Staszewski; Anna Stasiak; Tadeusz Karcz; Daniel McNaught Flores; Wiesława Agnieszka Fogel; Katarzyna Kieć-Kononowicz; Rob Leurs; Krzysztof Walczyński
Journal:  Medchemcomm       Date:  2019-01-11       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.